Daftar Pustaka

1. Epstein J. Pathology of prostatic neoplasia. In: Wein A, Kovoussi L, Novick A, et al. (eds)
Campbell-Walsh Urology. Philadelphia, 2007, pp. 2874–82.

2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:
GLOBOCAN 2008. Int J Cancer 2010; 127: 2893– 2917.

3. Mottet N, Schalken J, Heidenreich A, et al. Highlights on Prostate Cancer from Urological and
Oncological Congresses in 2007. Eur Urol Suppl 2008; 7: 460–73.

4. Murai M, Cheng C, Khauli R, et al. Prostate cancer: 6th international consultation on new
developments in prostate cancer and prostate diseases. 2006. Epub ahead of print 2006. DOI:
10.1016/j.juro.2007.01.121.

5. Klein E, Platz E, Thompson I. Epidemiology, Etiology, and Prevention of Prostate Cancer. In:
Wein A, Kovoussi L, Novick A, et al. (eds) Campbell-Walsh Urology. Philadelphia, 2007, pp.
2854–73.

6. Indonesian Society of Urologic Oncology (ISUO). ISUO Meeting 2011. 2011.

7. Kelompok Kerja Kanker Urologi RS. Cipto Mangunkusumo - RS. Kanker Dharmais. Panduan
pengelolaan kanker prostat. Interna Publishing, 2009.

8. Umbas R, Muchtar C, Hamid R. Terapi radikal pada penderita kanker prostat: tindak lanjut
jangka panjang dan faktor prediksi survival. Indones J Cancer 2010; 4: 55–60.

9. Paulsen F. & J. Waschke. 2013. Sobotta Atlas Anatomi Manusia : Anatomi Umum dan
Muskuloskeletal. Penerjemah : Brahm U. Penerbit. Jakarta : EGC.

10. Pearce, C, Evelyn, 2009. Anatomi dan fisiologi untuk paramedis, Jakarta : Gramedia.

11. Gann PH. Risk factors for prostate cancer. Rev Urol 2002; 4 Suppl 5: S3–S10.

12. Wolk A. Diet, lifestyle and risk of prostate cancer. Acta Oncol 2005; 44: 277–81.

13. Kolonel L. Fat, meat, and prostate cancer. Epidemiol Rev 2001; 23: 72–81.

14. Giovannucci E, Rimm E, Wolk A. Calcium and fructose intake in relation to risk of prostate
cancer. Cancer Res 1998; 58: 442–7.

15. Ostrander EA, Udler MS. The role of the BRCA2 gene in susceptibility to prostate cancer
revisited. Cancer Epidemiol Biomarkers Prev 2008; 17: 1843–1848.

16. Cavanagh H, Rogers KMA. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic
and stomach cancers. Hered Cancer Clin Pract 2015; 13: 16.

17. Plaskon LA, Penson DF, Vaughan TL, et al. Cigarette Smoking and Risk of Prostate Cancer in
Middle-Aged Men 1. 2003; 12: 604–609.

18. Huncharek M, Sue Haddock K, Reid R, et al. Smoking as a risk factor for prostate cancer: A
meta-analysis of 24 prospective cohort studies. Am J Public Health 2010; 100: 693–701.
19. Richie J, Catalona W, Ahmann F, et al. Effect of patient age on early detection of prostate
cancer with serum prostate-spesific antigen and digital rectal examination. Urology 1993; 42: 356–
74.

20. Carvalhal G, Smith D, Mager D, et al. Digital rectal examination for detecting prostate cancer
at prostate specific antigen levels of 4 ng/ml or less. J Urol 1999; 161: 835–9.

21. Stamey T, Yang N, Hay A, et al. Prostate-specific antigen as a serum marker for
adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16.

22. Catalona W, Richie J, Ahmann F, et al. Comparison of digital rectal examination and serum
prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical
trial of 6,630 men. J Urol 1994; 151: 1283–90.

23. Lee F, Torp-Pedersen S, Siders D, et al. Transrectal ultrasound in the diagnosis and staging of
prostate cancer. Radiology 1989; 170: 609– 15.

24. Monn MF, Flack CK, Koch MO. NCCN Guidelines: Prostate Cancer. Version 3.2. Prostate
Cancer 2016; 551–562.

25. Epstein J. An update of the Gleason grading system. J Urol 2010; 183: 433–440.

26. Edge S, Byrd D, Compton C, et al. (eds). AJCC cancer staging manual. 7th ed. Springer, 2010.

27. Spigelman S, McNeal J, Freiha F. Rectal examination in volume determination of carcinoma

of the prostate: clinical and anatomical correlations. J Urol 1986; 136: 1228–30.

28. Lee N, Newhouse J, Olsson C, et al. Which patients with newly diagnosed prostate cancer need
a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients.
Urology 1999; 54: 490–4.

29. Jager G, Severens J, Thornbury J. Prostate cancer staging: should MR imaging be used? A
decision analytic approach. Radiology 2000; 215: 445–51.

30. Partin A, Mangold L, Lamm D. Contemporary update of the prostate cancer staging
nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843–8.

31. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients

undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167:
1681–6.

32. McGregor B, Tulloch A, Quinlan M. The role of bone scanning in the assessment of prostatic
carcinoma. Br J Urol 1978; 50: 178–81.

33. O’Donoghue E, Constable A, Sherwood T. Bone scanning and plasma phosphatases in

carcinoma of the prostate. Br J Urol 1978; 50: 172–7.

34. Wolff J, Zimny M, Borchers H. Is prostate-specific antigen a reliable marker of bone

metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998; 33: 376–81.

35. Bruwer G, Heyns C, Allen F. Influence of local tumour stage and grade on reliability of serum
prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the
prostate. Eur Urol 1999; 35: 223–7.